42.25

0.93% 0.39

After Hours: 42.25

Harmony Biosciences Holdings Inc (HRMY)

Overview News Price History Option Chain Financials Why HRMY Down? Discussions Forecast

Harmony Biosciences Holdings Inc stock is traded at $42.25, with a volume of 659.59K. It is up +0.93% in the last 24 hours and up +8.95% over the past month. Harmony Biosciences Holdings Inc is a commercial-stage pharmaceutical company focused on developing and commercializing therapies for patients living with rare neurological diseases who have unmet medical needs. The company has one reportable segment: rare neurological diseases. Its product WAKIX (pitolisant) is a molecule with a novel mechanism of action specifically designed to increase histamine signaling in the brain by binding to H3 receptors and is used for the treatment of cataplexy in adult patients with narcolepsy. The other drug candidates in its pipeline are Pitolisant, HBS-102 (MCHR1 antagonist), BP1.15205 (orexin-2 receptor agonist), ZYN002 (cannabidiol gel), EPX-100 (clemizole hydrochloride), and EPX-200 (lorcaserin), among others.

Previous Close:

$41.86

Open:

$41.5

24h Volume:

659.59K

Relative Volume:

0.81

Market Cap:

$2.46B

Revenue:

$899.11M

Net Income/Loss:

$145.62M

P/E Ratio:

17.02

EPS:

2.4829

Net Cash Flow:

$322.54M

1W Performance:

+7.75%

1M Performance:

+8.95%

6M Performance:

+48.04%

1Y Performance:

+16.39%

1-Day Range:

$41.36

$42.34

1-Week Range:

$38.97

$43.49

52-Week Range:

$25.52

$43.49

Harmony Biosciences Holdings Inc Stock (HRMY) Company Profile

Name

Harmony Biosciences Holdings Inc

Sector

Healthcare (1074)

Industry

Biotechnology (600)

Phone

(484) 539-9800

Address

630 W GERMANTOWN PIKE, PLYMOUTH MEETING

Employee

293

Twitter

Next Earnings Date

2026-08-04

Latest SEC Filings

HRMY's Discussions on Twitter

Compare HRMY vs VRTX, REGN, ARGX, MRNA, RVMD

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
HRMY Harmony Biosciences Holdings Inc	42.25	2.22B	899.11M	145.62M	322.54M	2.4829
VRTX Vertex Pharmaceuticals Inc	546.12	136.93B	12.34B	4.34B	3.71B	16.87
REGN Regeneron Pharmaceuticals Inc	827.72	85.11B	14.92B	4.42B	3.79B	41.04
ARGX Argen X Se Adr	1,033.15	64.95B	4.16B	1.29B	734.26M	19.58
MRNA Moderna Inc	145.55	53.23B	2.23B	-3.19B	-1.60B	-8.1462
RVMD Revolution Medicines Inc	210.02	45.38B	742.00K	-1.37B	-1.07B	-7.0731

Harmony Biosciences Holdings Inc Stock (HRMY) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Feb-23-26	Downgrade	Deutsche Bank	Buy → Hold
Feb-23-26	Downgrade	Truist	Buy → Hold
Feb-11-26	Resumed	UBS	Neutral
Jul-21-25	Initiated	Truist	Buy
Jul-10-25	Resumed	Goldman	Neutral
Jun-02-25	Resumed	Oppenheimer	Outperform
Feb-11-25	Initiated	Deutsche Bank	Buy
Dec-17-24	Initiated	H.C. Wainwright	Buy
Oct-10-24	Resumed	Raymond James	Outperform
Sep-10-24	Initiated	UBS	Buy
Jun-21-24	Initiated	Citigroup	Buy
Jan-02-24	Downgrade	BofA Securities	Neutral → Underperform
Sep-25-23	Downgrade	Goldman	Neutral → Sell
Sep-07-23	Initiated	Berenberg	Buy
Apr-20-23	Initiated	BofA Securities	Neutral
Oct-14-22	Upgrade	Janney	Neutral → Buy
Oct-14-22	Upgrade	Jefferies	Hold → Buy
Aug-03-22	Downgrade	Jefferies	Buy → Hold
Jul-13-22	Downgrade	Goldman	Buy → Neutral
Jul-07-22	Initiated	Mizuho	Buy
Apr-14-22	Initiated	Cantor Fitzgerald	Overweight
Dec-01-21	Initiated	Oppenheimer	Outperform
Nov-04-21	Initiated	Raymond James	Outperform
Sep-23-21	Initiated	Needham	Buy
Mar-29-21	Upgrade	Goldman	Neutral → Buy
Sep-14-20	Initiated	Goldman	Neutral
Sep-14-20	Initiated	Jefferies	Buy
Sep-14-20	Initiated	Piper Sandler	Overweight

View All

Harmony Biosciences Holdings Inc Stock (HRMY) Latest News

Aug 21, 2026

Virtus Advisers LLC Makes New Investment in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 21, 2026

Aug 20, 2026

Tieton Capital Management LLC Takes Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Denali Advisors LLC Purchases 29,700 Shares of Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Stephen M. Mollichella Net Worth (2026) - GuruFocus

Aug 20, 2026

Aurora Investment Counsel Invests $2.37 Million in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 20, 2026

Harmony Biosciences Holdings, Inc. (NASDAQ:HRMY) Given Consensus Recommendation of "Hold" by Analysts - MarketBeat

Aug 20, 2026

Aug 17, 2026

Did Strong Q2 Earnings and Completed Buybacks Just Shift Harmony Biosciences' (HRMY) Investment Narrative? - simplywall.st

Aug 17, 2026

Chase Investment Counsel Corp Takes $1.82 Million Position in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 17, 2026

Aug 16, 2026

Harmony Biosciences (NASDAQ:HRMY) Rating Increased to Strong-Buy at Wall Street Zen - MarketBeat

Aug 16, 2026

Aug 15, 2026

HRMY Stock On Track For Best Intraday Gains In 18 Months — What Did Mizuho Analysts Say? - stocktwits.com

Aug 15, 2026

Aug 14, 2026

Harmony Biosciences Highlights Record WAKIX Growth, Advances Orexin and Epilepsy Pipeline - MarketBeat

Aug 14, 2026

Aug 13, 2026

HRMY: Record WAKIX sales drive CNS pipeline progress, with BP-205 and new pitolisant forms advancing - TradingView

Aug 13, 2026

Analysts Are Bullish on Top Healthcare Stocks: Aura Biosciences Inc (AURA), Corbus Pharmaceuticals (CRBP) - The Globe and Mail

Aug 13, 2026

Zacks Research Downgrades Harmony Biosciences (NASDAQ:HRMY) to Hold - MarketBeat

Aug 13, 2026

Aug 12, 2026

Harmony Biosciences Holdings, I (HRMY) Stock Forecasts - Yahoo Finance

Aug 12, 2026

Harmony Sets Investor Appearance as CNS Strategy Advances - MyChesCo

Aug 12, 2026

Hennion & Walsh Asset Management Inc. Decreases Stock Holdings in Harmony Biosciences Holdings, Inc. $HRMY - MarketBeat

Aug 12, 2026

Aug 11, 2026

Harmony Biosciences Holdings (HRMY) Stock Analysis: Exploring an 18% Potential Upside with Strong Revenue Growth - DirectorsTalk Interviews

Aug 11, 2026